Neonatal Phase 1 Valacyclovir Study

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

June 8, 2025

Study Completion Date

July 10, 2025

Conditions
Herpes Simplex
Interventions
DRUG

Valacyclovir

Valacyclovir is a L-valyl ester of acyclovir.

Trial Locations (12)

11040

Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease, Queens

28207

Atrium Health ID Consultants & Infusion Care Specialists, Charlotte

40202

University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville

55454

M Health Fairview Masonic Children's Hospital, Minneapolis

35233-0011

Children's of Alabama Child Health Research Unit (CHRU), Birmingham

30322-1014

Emory University School of Medicine, Atlanta

63110-1010

Washington University in St. Louis, St Louis

68114-4108

Children's Nebraska, Omaha

14642-0001

University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester

13210-2342

SUNY Upstate Medical University Hospital - Pediatrics, Syracuse

43205-2664

Nationwide Children's Hospital, Columbus

53226-3522

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH